The compositions and methods are described for generating an immune response to an antigen. The compositions and methods described herein relate to a modified vaccinia Ankara (MVA) vector encoding one or more viral antigens as a fusion product with a viral glycoprotein and matrix protein for generating a protective immune response to a subject to which the vector is administered. The compositions and methods of the present invention are useful both prophylactically and therapeutically and may be used to prevent and/or treat diseases.

The invention described herein relates to methods for treating a patient having a plurality of HLA-negative cancer cells or cancer cells with reduced HLA expression with IFN-alpha in an amount sufficient to expand and/or activate immune cells such that the activated and/or expanded immune cells kill one or more of HLA-negative cancer cells or the cancer cells with reduced HLA expression.

The invention covers the use of certain classes of lipids including cationic lipids in ex-vivo dendritic cell therapies. The cationic lipids enhance antigen uptake, processing and presentation of the processed antigens by dendritic cells to CD8+ and CD4+ T-cells via the MHC classes I and II presentation pathways respectively. Antigen uptake via cationic lipid by dendritic cells result in significant lowering of the population of the immune suppressive regulatory T cells in the tumors and a significant increase of the tumor targeting cytotoxic T-cells. Loss of regulatory T cells and increase of tumor specific cytotoxic cells are conducive to effective elimination of the tumors.

This disclosure relates to methods of treating cancer using dendritic cells pulsed with tumor membrane vesicles as disclosed herein. In certain embodiments, the tumor membrane vesicles contain fusion proteins with a cytokine and a glycosyl phosphatidylinositol domain. In certain embodiments, the cytokine is granulocyte-macrophage colony-stimulating factor (GM-CSF). In certain embodiments, tumor membrane vesicles contain fusion proteins with IL-12 and a glycosyl phosphatidylinositol domain.

Disclosed herein are vaccine compostions and method to use the same. The compositions and methods disclosed herein provide means to prevent and/or treat a variety of cancers.

The present invention provides a chimeric cytokine receptor (CCR) comprising: (i) an exodomain which binds to a ligand selected from a tumour secreted factor, a chemokine and a cell-surface antigen; and (ii) a cytokine receptor endodomain.

Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.

Use of a CXCR4 antagonistic peptide and an immune-check point regulator in the treatment of cancer is provided. Accordingly there is provided a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a peptide having an amino acid sequence as set forth in SEQ ID NO: 1 or an analog or derivative thereof; and a therapeutically effective amount of a PD1 antagonist, a PDL-1 antagonist, a CTLA-4 antagonist, a LAG-3 antagonist, a TIM-3 antagonist, a KIR antagonist, an IDO antagonist, an OX40 agonist, a CD137 agonist, a CD27 agonist, a CD40 agonist, a GITR agonist, a CD28 agonist or an ICOS agonist, thereby treating the cancer in the subject. Also provided are pharmaceutical compositions and articles of manufacture.

The invention relates to antibodies, and antigen-binding fragments thereof, that specifically bind TFPI and inhibit an activity thereof. Such antibodies and fragments are useful for treating bleeding disorders and shortening clotting time.

The present invention relates to a recombinant vaccine against Lawsonia intracellularis, based on a recombinant synthetic chimeric variant of membrane proteins and invasins of said bacteria. In addition, the invention discloses synthetic nucleotide sequences encoding said protein variants, recombinant proteins as such, an expression cassette of said synthetic protein antigens, a transformed cell, and a method for producing said antigens, demonstrating the antigenicity and protective potential thereof against the pathogen Lawsonia intracellularis.